Welcome, Introduction, Polling Questions
Overview of CLL/SLL and Treatment Algorithms
- Standard-of-care first-line and second-line regimens
- Key variables in deciding between regimens
- Mechanisms, pharmacokinetics, pharmacodynamics, and efficacy of currently available BTK inhibitors
- Covalent vs non Covalent BTK inhibitors
- Investigational next-generation BTKis in development
Effective Management of AEs
- Starting systemic therapy in suitable patients
- Promoting adherence with oral therapy
- AE profiles and management guides and resources
Summary, Final Thoughts, Audience Q&A
Date / Time
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Nicole Lamanna, MD
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
The goal of this activity is to improve the knowledge, competence, and confidence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTKi in the care of their patients with CLL/SLL.
This educational program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
- Compare first-generation and next-generation BTK inhibitors in terms of molecular characteristics, binding, targeted selectivity, approved indications, dosing, safety profile, and efficacy
- Plan BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL, taking into consideration guidelines, expert recommendations, and recent practice-changing clinical trial results
- Select optimal BTK inhibitor–based therapy in relapsed/refractory CLL/SLL for appropriate patients following progression on or intolerance of first-line or subsequent therapies
- Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation and to maximize patient survival and quality of life
- Identify patients eligible for ongoing clinical trials evaluating currently available and emerging BTK inhibitors and BTK inhibitor–based combinations
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-076-L01-P
Type of Activity: Knowledge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.